Comparing Prostate Cancer Guidelines – Guidelines Side-By-Side
Prostate cancer continues to be the most prevalent non-cutaneous cancer among men in the United States (US), with an estimated 268,490 new cases and 34,500 deaths projected for 2022. Given that the majority of newly diagnosed prostate cancer patients present with localized disease, it is crucial to provide evidence-based guideline statements to guide clinical decision-making […]